Database : HANSEN Search on : TERAP [Subject descriptor] References found : 1796 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 90

go to page

1 / 1796

HANSEN

select to print

Id: 19948 Author: Ganapati, R; Pai, V. V; Shroff, H. J; Gandewar, Kailas. Title: Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions. Source: Int. J. Lepr;65(2):264-266, Jun. 1997. tab, graf. Descriptors: Hanseníase Dimorfa/quimioter Hanseníase Dimorfa/microbiol Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/microbiol Rifampina/uso terap Ofloxacino/uso terap Location: BR191.1

2 / 1796

HANSEN

select to print

Id: 19947 Author: Pavithran, K; Satish, T. C. Title: Dapsone-induced motor polyneuropathy in a patient with leprosy. Source: Int. J. Lepr;65(2):262-263, Jun. 1997. . Descriptors: Hanseníase Dimorfa/quimioter Dapsona/ef adv Dapsona/uso terap Doença dos Neurônios Motores/ind quim Doença dos Neurônios Motores/diag Limits: Humanos Masculino Feminino Location: BR191.1

3 / 1796

HANSEN

select to print

Id: 19942 Author: Toral, Esteban Moreno; Diaz, M. Teresa Lopez. Title: The influence of the San Lazaro Hospital of Seville in the creation and management techniques of the "Lazaretto" Hospitals in the Americas. Source: Int. J. Lepr;65(2):252-256, Jun. 1997. . Abstract: The San Lazaro Hospital of Seville that was established in the middle of the 13th century was one of the most important in Spain and Europe throughout nearly eight centuries in terms of caring for leprosy patients. In the 1930s the exclusive treatment of leprosy patients ceased and San Lazaro became a general hospital. The Spanish Crown (Alfonso X) accorded certain privileges and rules to the hospital which also were conferred by subsequent monarchs. These rules and ordinances contributed to the establishment and functioning of many lazarettos throughout the Americas of which we have documentation, notably those of Santo Domingo, Tlaxplana (Mexico City), Lima, Cartagena de Incias, La Habana, and Yucatan. (AU)^ien. Descriptors: Hanseníase/hist Hanseníase/terap Hospitais de Dermatologia Sanitária de Patologia Tropical/hist Location: BR191.1

4 / 1796

HANSEN

select to print

Id: 19938 Author: Mane, Ibrahima; Cartel, Jean-Louis; Grosset, Jacques-Henri. Title: Field trial on efficacy of supervised monthly dose of 600mg rifampin, 400mg ofloxacin and 100mg minocycline for the treatment of leprosy; first results. Source: Int. J. Lepr;65(2):224-229, Jun. 1997. tab. Abstract: In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy. During the first year of the trial, 220 patients with active leprosy (newly detected or relapsing after dapsone monotherapy) were recruited: 102 paucibacillary (PB) (60 males and 42 females) and 118 multibacillary (MB) (71 males and 47 females). All of them accepted the new treatment (none requested to be preferably put under standard WHO/MDT), no clinical sign which could be considered as a toxic effect of the drug was noted, and none of the patients refused to continue treatment because of any clinical trouble. The compliance was excellent: the 113 patients (PB and MB) detected during the first 6 months of the trial have taken six monthly doses in 6 months, as planned. The rate of clearance and the progressive decrease of cutaneous lesions was satisfactory. Although it is too soon to give comprehensive results, it should be noted that no treatment failure was observed in the 56 PB patients who have completed treatment and have been followed up for 6 months. The long-term efficacy of the new regimen is to be evaluated on the rate of relapse during the years following the cessation of treatment. If that relapse rate is acceptable (similar to that observed in patients after treatment with current standard WHO/ MDT), the new regimen could be a solution to treat, for instance, patients very irregular and/or living in remote or inaccessible areas since no selection of rifampin-resistant Mycobacterium leprae should be possible (a monthly dose of ofloxacin and minocycline being as effective as a dose of dapsone and clofazimine taken daily for 1 month). Nevertheless, until longer term results of this and other trials become available, there is no justification for any change in the treatment strategy, and all leprosy patients should be put under standard WHO/MDT. (AU)^ien. Descriptors: Hanseníase/quimioter Rifampina/admin Rifampina/ef adv Rifampina/uso terap Ofloxacino/admin Ofloxacino/ef adv Ofloxacino/uso terap Minociclina/admin Minociclina/ef adv Minociclina/uso terap Limits: Humanos Masculino Feminino Location: BR191.1

5 / 1796

HANSEN

select to print

Id: 19930 Author: Celik, Onur; Yalcin, Sinasi; Gok, Uzeyir; Yavrucuoglu, Emel; Ozturk, Ahmet; Akyol, Ali. Title: Auditory brain stem evoked potentials in patients with leprosy. Source: Int. J. Lepr;65(2):166-169, Jun. 1997. tab. Abstract: Nineteen, randomly selected male patients with lepromatous leprosy were evaluated electrophysiologically. All of these patients had long-standing disease and were treated with dapsone alone. There were statistically significant differences between the values obtained in this group of leprosy patients compared to 20 age-matched controls in auditory brain stem evoked potentials (ABEP). The findings are consistent with a pathologic process located mainly between the cochlear nucleus and the lateral lemniscus in the auditory brain stem pathways. It should be emphasized that our patients had long-standing disease which was treated with dapsone. ABEP could very well be different in leprosy patients diagnosed early and treated for relatively short periods with multidrug therapy. Brain stem evoked response audiometry may be useful for evaluating the possibility of brain stem involvement in leprosy. (AU)^ien. Descriptors: Hanseníase Virchowiana/diag Hanseníase Virchowiana/quimioter Hansenostáticos/uso terap Location: BR191.1

6 / 1796

HANSEN

select to print

Id: 19913 Author: Chaudhury, Sachin; Hajra, Sunil Kumar; Mukerjee, Ashutosh; Saha, Bibbuti; Majumdar, Vibek; Chattapadhya, Debasis; Saha, Kunal. Title: Immunotherapy of lepromin-negative borderline leprosy patients with low-dose convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta. Source: Int. J. Lepr;65(1):56-62, Mar., 1997. tab. Abstract: The present report, which describes management of lepromin-negative borderline leprosy patients with low-dose Convit vaccine, is an extension of our earlier study on the treatment of lepromatous leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy (MDT). The test Group I, consisting of 50 lepromin-negative, borderline leprosy patients, were given low-dose Convit vaccine plus MDT. The control group II consisted of 25 lepromin-negative, borderline leprosy patients given BCG vaccination plus MDT and 25 lepromin-negative, borderline leprosy patients given killed Mycobacterium leprae (human) vaccine plus MDT. The control group III consisted of 50 lepromin-positive, borderline leprosy patients not given any immunostimulation but given only MDT. Depending upon the lepromin unresponsiveness, the patients were given one to four inoculations of the various antileprosy vaccines and were followed up every 3 months for 2 years for clinical, bacteriological and immunological outcome. All patients belonging to the test and control groups showed clinical cure and bacteriological negativity within 2 years. However, immunologic potentiation, assessed by lepromin testing and the leukocyte migration inhibition test (LMIT), was better in the test patients receiving low-dose Convit vaccine plus MDT than in the control patients receiving BCG vaccine plus MDT or killed M. leprae vaccine plus MDT or MDT alone. But the capacity of clearance bacteria (CCB) test from the lepromin granuloma showed poor bacterial clearance in the test patients. However, there was no relapse during 6 years of follow up. Two mid-borderline (BB) patients had severe reversal reactions with lagophthalmos and wrist drop during immunotherapy despite being given low-dose Convit vaccine. (AU)^ien. Descriptors: Hanseníase Dimorfa/quimioter Hanseníase Dimorfa/terap Mycobacterium leprae/imunol Limits: Humanos Masculino Feminino Location: BR191.1

7 / 1796

HANSEN

select to print

Id: 19892 Author: Anon. Title: Recomendações para pessoas atingidas pela hanseníase / ? Source: In: Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica.Autocuidado em Hanseníase: face, mãos e pés^ipt. Brasília, Editora do Minist´rio da Saúde, 2010. p.70-70. Descriptors: Hanseníase/prev Hanseníase/reabil Hanseníase/terap Location: BR191.1, B736a

8 / 1796

HANSEN

select to print

Id: 19887 Author: Anon. Title: Controlando a hanseníase: um desafio para o SUS no Instituto Lauro de Souza Lima / ? Source: In: São Paulo(Estado). Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças.Vigilância em Saúde: 20 anos SUS-SP^ipt. São Paulo, s.n, 2008. p.51-61ilus. Descriptors: Hanseníase/epidemiol Hanseníase/prev Hanseníase/terap Location: BR191.1, S63v

9 / 1796

HANSEN

select to print Texto Completo-en

Id: 19878 Author: Ji, Baohong. Title: Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks. Source: Int. J. Lepr;66(3):391-391, Sept. 1998. . Descriptors: Hanseníase/quimioter Hansenostáticos/admin Hansenostáticos/uso terap Limits: Humanos Masculino Feminino Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3cor03.pdf / en Location: BR191.1

10 / 1796

HANSEN

select to print Texto Completo-en

Id: 19870 Author: Roche, Paul W; Theuvenet, Wim J; Le Master, Joseph W; Butlin, C. Ruth. Title: Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone. Source: Int. J. Lepr;66(3):340-347, Sept. 1998. tab. Abstract: The changes in nerve function tests in 297 new leprosy patients over an average period of 30 months were measured. The impact of type 1 reactions (T1R) on sensory and voluntary muscle function was measured by standard tests. Sensory function was improved in patients with single episodes of cutaneous T1R, but not improved in patients with neural T1R or with multiple episodes of either kind of T1R. Patients over 40 years of age improved less than younger patients, and patients admitted for treatment of T1R improved more than those treated as outpatients. These data point to a need to find better regimens for the treatment of nerve damage in T1R. (AU)^ien. Descriptors: Hanseníase Dimorfa/quimioter Hanseníase Dimorfa/fisiopatol Neurônios Motores/fisiol Neurônios Eferentes/fisiol Prednisolona/uso terap Limits: Humanos Masculino Feminino Criança Adolescente Adulto Idoso Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3a04.pdf / en Location: BR191.1

11 / 1796

HANSEN

select to print Texto Completo-en

Id: 19867 Author: Zodpey, Sanjay P; Shrikhande, Sunanda N; Salodkar, Atul D; Maldhure, Bhagirath R; Kulkarni, Shyam W. Title: Effectiveness of Bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India. Source: Int. J. Lepr;66(3):309-315, Sept. 1998. tab. Abstract: A hospital-based, pair-matched, casecontrol study was carried out at Government Medical College Hospital in Nagpur in central India to estimate the effectiveness of BCG vaccination in the prevention of leprosy. The study included 314 incidence cases of leprosy [diagnosed by World Health Organization (WHO) criteria] below the age of 32 years. Each case was pair matched with one control for age, sex and socioeconomic status. Controls were selected from subjects attending this hospital for conditions other than tuberculosis and leprosy. A significant protective association between BCG and leprosy was observed (OR 0.29, 95% CI 0.21-0.41). The vaccine effectiveness (VE) was estimated to be 71% (95% CI 59-79). The BCG effectiveness against multibacillary and paucibacillary leprosy was 79% (95% CI 60-89) and 67% (95% CI 45-78), respectively. It was more effective during the first decade of life (VE 74%; 95% CI 38-90), among females (VE 82%; 95% CI 64-90), and in the lower socioeconomic strata (VE 75%; 95% CI 32-92). The prevented fraction was calculated to be 51% (95% CI 38-62). In conclusion, this study has identified a beneficial role of BCG vaccination in the prevention of leprosy in central India. (AU)^ien. Descriptors: Hanseníase/prev Vacina BCG/uso terap Limits: Humanos Masculino Feminino Adolescente Adulto Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3a01.pdf / en Location: BR191.1

12 / 1796

HANSEN

select to print Texto Completo-en

Id: 19864 Author: Anon. Title: Rehabilitation. Source: Int. J. Lepr;66(4):138A-143A, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hanseníase/reabil Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs12.pdf / en Location: BR191.1

13 / 1796

HANSEN

select to print Texto Completo-en

Id: 19863 Author: Anon. Title: Psycho-Social. Source: Int. J. Lepr;66(4):127A-137A, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hanseníase/psicol Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs11.pdf / en Location: BR191.1

14 / 1796

HANSEN

select to print Texto Completo-en

Id: 19836 Author: Richardus, J. H; Virmond, M. Title: Report of workshop on prevention of disability. Source: Int. J. Lepr;66(4):576-576, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hanseníase/compl Hanseníase/terap Pessoas com Deficiência/reabil Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur01.pdf / en Location: BR191.1

15 / 1796

HANSEN

select to print Texto Completo-en

Id: 19833 Author: Jacobson, Robert R. Title: Report of workshop on defining the disease and antibacterial therapy. Source: Int. J. Lepr;66(4):572-573, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hansenostáticos/uso terap Hanseníase/quimioter Hanseníase/prev Mycobacterium leprae/ef drogas Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur01.pdf / en Location: BR191.1

16 / 1796

HANSEN

select to print Texto Completo-en

Id: 19774 Author: Anon. Title: Current literature. Source: Int J Lepr;57(2):564-597, June 1989. . Descriptors: Hanseníase/diag Hanseníase/prev Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2curlit.pdf / en Location: Br191.1

17 / 1796

HANSEN

select to print Texto Completo-en

Id: 19767 Author: Becx-Bleuminck, Marijke. Title: Operational aspects of multidrug therapy. Source: Int J Lepr;57(2):540-551, June 1989. ^btab. Descriptors: Hanseníase/quimioter Rifampina/uso terap Amidas/uso terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2soalec02.pdf / en Location: Br191.1

18 / 1796

HANSEN

select to print Texto Completo-en

Id: 19757 Author: Girdhar, Anita; Mishra, Brajendra; Lavania, Ravinder K; Bagga, Ashok K; Malaviya, Govind N; Girdhar, Bhawneshwar K. Title: Leprosy in infants - report of two cases. Source: Int J Lepr;57(2):472-475, June 1989. ^bilus. Descriptors: Hanseníase/diag Hanseníase/quimioter Hanseníase/patol Rifampina/uso terap Dapsona/uso terap Limits: Humanos Feminino Lactente Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a04.pdf / en Location: Br191.1

19 / 1796

HANSEN

select to print Texto Completo-en

Id: 19755 Author: Katoch, Kiran; Ramanathan, Usha; Natrajan, Mohan; Bagga, Ashok K; Bhatia, AS; Saxena, RK; Ramu, Gopal. Title: Relapses in paucibacillary patients after treatment with three short term regimens containing rifampin. Source: Int J Lepr;57(2):458-464, June 1989. ^btab. Abstract: Three multidrug regimens all containing rifampin and dapsone have been tried for the treatment of 278 cases of paucibacillary leprosy. Regimen I was the one recommended by the WHO Study Group. Regimen II was the same as Regimen I with depsone alone continued for a further 6 months. Regimen III was the same as Regimen II but rifampin was given daily for the first 7 days. The patients were comparable with regard to disease classification, lepromin status, bacteriological status, and number of lesions. As reported earlier, the disease inactivity rates by 1 year of treatment were much greater with Regimens II and III than with Regimen I (94% and 97% vs 76%). Early reaction was seen in 6% of those in Regimen III and in none in Regimens I and II. Late reaction was observed in 9% of those in Regimen I and none in Regimens II and III. During 3 1/2 years of follow up, 13% of the cases in Regimen I, 1% in Regimen II, and 2% in Regimen III relapsed. Since the patients in the three regimens were otherwise comparable, it is concluded that the high inactivity rate, low relapse rate (1%-2%), and no early or late reaction as observed in Regimen II patients were because of adequate treatment^ien. Descriptors: Dapsona/admin Dapsona/uso terap Rifampina/admin Rifampina/uso terap Hanseníase/microbiol Hanseníase/patol Limits: Humanos Masculino Feminino Adulto Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a02.pdf / en Location: Br191.1

20 / 1796

HANSEN

select to print Texto Completo-en

Id: 19754 Author: Katoch, Kiran; Ramu, Gopal; Ramanathan, Usha; Sengupta, Utpal; Sharma, Vishnu D; Shivannavar, Channappa T; Katoch, Vishwa M. Title: Results of a modified WHO regimen in highly bacilliferous BL/LL patients. Source: Int J Lepr;57(2):451-457, June 1989. ^bgraf, ^btab. Abstract: regimen consisting of 600 mg of rifampin once a month, 100 mg of clofazimine on alternate days, and 100 mg of dapsone daily was used in 56 untreated, highly bacillated borderline lepromatous/lepromatous (BL/LL) patients with an average bacterial index (BI) of 4.45. Treatment was continued until skin-smear negativity. After 2 years of therapy, none of the patients had become smear negative and the average BI was 2.56. There was no growth on inoculation of skin-tissue biopsies in the normal mouse foot pad after 6 months of therapy. Bacillemia was still detectable in 11/50 patients, and significant ATP levels were detected in Mycobacterium leprae from skin-tissue biopsies in 16% of the cases. After 3 years of therapy, three patients had become smear negative. The average BI was 1.30. None of the patients had detectable bacillemia, and 5% of the cases showed detectable ATP levels in M. leprae from tissue biopsies. After 4 years of therapy, 41.7% of the patients had become smear negative. The average BI was 0.66, and no ATP was detected in any of the purified bacillary suspensions. The fall in BI was accelerated, and more patients on continued treatment became negative earlier compared to those having treatment for a limited duration, as reported by others^ien. Descriptors: Clofazimina/admin Clofazimina/uso terap Dapsona/admin Dapsona/uso terap Hanseníase Dimorfa/microbiol Hanseníase Virchowiana/microbiol Limits: Humanos Adolescente Adulto Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a01.pdf / en Location: Br191.1

---

page 1 de 90

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information